The safety and adverse event profile of favipiravir in the treatment of COVID-19 patients, Turkey
Description
CONCLUSIONS: Serious AEs were detected at very low levels that would not require discontinuation of treatment or any AE-related death. Since SARS-CoV-2 itself and drug interactions may differ, FVP-related AEs might vary in COVID-19 patients. Our
